|
|
Blood, 1 November 2004, Vol. 104, No. 9, pp. 2661-2666.
Prepublished online as a Blood First Edition Paper on July 6, 2004; DOI 10.1182/blood-2004-04-1319.
 Previous Article | Next Article 
Submitted April 7, 2004
Accepted June 13, 2004
Prognostic and biological significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma
Norma C Gutierrez, Juan L Garcia, Jesus M Hernandez, Eva Lumbreras, Mariana Castellanos, Ana Rasillo, Gema Mateo, Jose M Hernandez, Sonia Perez, Alberto Orfao, and Jesus F San Miguel Izquierdo*
Department of Hematology, University Hospital, Salamanca, Spain; Cancer Research Center, University of Salamanca, Salamanca, Spain
Department of Hematology, General Hospital, Segovia, Spain
* Corresponding author; email: sanmigiz{at}gugu.usal.es.
Cytogenetic abnormalities, evaluated either by karytoype or by fluorescence in situ hybridization (FISH), are considered to be the most important prognostic factor in multiple myeloma (MM). However, there is no information about the prognostic impact of genomic changes detected by comparative genomic hybridization (CGH). We have analyzed the frequency and prognostic impact of genetic changes as detected by CGH and evaluated the relationship between these chromosomal imbalances and IGH translocation, analyzed by FISH, in 74 patients with newly diagnosed MM. Genomic changes were identified in 51 out of the 74 MM patients (69%). The most recurrent abnormalities among the cases with genomic changes were gains on chromosome regions 1q (45%), 5q (24%), 9q (24%), 11q (22%), 15q (22%), 3q (16%), and 7q (14%), while losses mainly involved chromosomes 13 (39%), 16q (18%), 6q (10%) and 8p (10%). Remarkably, the six patients with gains on 11q had IGH translocations. Multivariate analysis selected chromosomal losses, 11q gains, age and type of treatment (conventional chemotherapy vs autologous transplantation) as independent parameters for predicting survival. Genomic losses retained the prognostic value irrespective of treatment approach. According to these results, losses of chromosomal material evaluated by CGH represent a powerful prognostic factor in MM patients.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Avet-Loiseau, C. Li, F. Magrangeas, W. Gouraud, C. Charbonnel, J.-L. Harousseau, M. Attal, G. Marit, C. Mathiot, T. Facon, et al.
Prognostic Significance of Copy-Number Alterations in Multiple Myeloma
J. Clin. Oncol.,
September 20, 2009;
27(27):
4585 - 4590.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. Leone, B. A. Walker, M. W. Jenner, L. Chiecchio, G. Dagrada, R. K.M. Protheroe, D. C. Johnson, N. J. Dickens, J. L. Brito, M. Else, et al.
Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications
Clin. Cancer Res.,
October 1, 2008;
14(19):
6033 - 6041.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Jenner, P. E. Leone, B. A. Walker, F. M. Ross, D. C. Johnson, D. Gonzalez, L. Chiecchio, E. Dachs Cabanas, G. Paolo Dagrada, M. Nightingale, et al.
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma
Blood,
November 1, 2007;
110(9):
3291 - 3300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Largo, B. Saez, S. Alvarez, J. Suela, B. Ferreira, D. Blesa, F. Prosper, M. J. Calasanz, and J. C. Cigudosa
Multiple myeloma primary cells show a highly rearranged unbalanced genome with amplifications and homozygous deletions irrespective of the presence of immunoglobulin-related chromosome translocations
Haematologica,
June 1, 2007;
92(6):
795 - 802.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Shaughnessy Jr, F. Zhan, B. E. Burington, Y. Huang, S. Colla, I. Hanamura, J. P. Stewart, B. Kordsmeier, C. Randolph, D. R. Williams, et al.
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
Blood,
March 15, 2007;
109(6):
2276 - 2284.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Agnelli, S. Bicciato, S. Fabris, L. Baldini, F. Morabito, D. Intini, D. Verdelli, A. Callegaro, F. Bertoni, G. Lambertenghi-Deliliers, et al.
Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma
Haematologica,
January 1, 2007;
92(1):
56 - 65.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-V. Mateos, J.-M. Hernandez, M.-T. Hernandez, N.-C. Gutierrez, L. Palomera, M. Fuertes, J. Diaz-Mediavilla, J.-J. Lahuerta, J. de la Rubia, M.-J. Terol, et al.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
Blood,
October 1, 2006;
108(7):
2165 - 2172.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Zhan, Y. Huang, S. Colla, J. P. Stewart, I. Hanamura, S. Gupta, J. Epstein, S. Yaccoby, J. Sawyer, B. Burington, et al.
The molecular classification of multiple myeloma
Blood,
September 15, 2006;
108(6):
2020 - 2028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Walker, P. E. Leone, M. W. Jenner, C. Li, D. Gonzalez, D. C. Johnson, F. M. Ross, F. E. Davies, and G. J. Morgan
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma
Blood,
September 1, 2006;
108(5):
1733 - 1743.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Hanamura, J. P. Stewart, Y. Huang, F. Zhan, M. Santra, J. R. Sawyer, K. Hollmig, M. Zangarri, M. Pineda-Roman, F. van Rhee, et al.
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
Blood,
September 1, 2006;
108(5):
1724 - 1732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
